Health experts believe that a new class of drugs known as GLP-1s, both the weight loss injections such as Ozempic, Wegovy and Mounjaro and (in the near future) pills of those same drugs, will have a significant role to play in transforming people's health and reducing obesity rates in the UK and in the US.
In this book, Dr David Cavan, a world-leading authority on all aspects of diabetes and the use of semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), reviews the history, development, safe use of, benefits and risks of the latest generation of this class of important medications: Wegovy, which is approved for use in the NHS, alongside diet and physical activity, to manage excess weight and obesity; Ozempic, which is used to treat type 2 diabetes and Mounjaro (tirzepatide) which, in theory, will be more effective than others, and is now approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for weight loss management by the NHS.
Up to date with a rigorous understanding of both the latest scientific research and public health policy and informed by years of clinical experience, this guide is rich in detail and patient experience. Dr Cavan gives the reader all the facts - so they are in the best possible position to make sensible decisions that help them to discuss with their doctor and achieve their health goals.
